Atrial Fibrillation Focused Update
The purpose of this document is to update the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” (2014 AF Guideline) in areas for which new evidence has emerged since its publication. The scope of this focused update includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section on catheter ablation of atrial fibrillation (AF), revisions to the section on the management of AF complicating acute coronary syndrome (ACS), and new sections on device detection of AF and weight loss. The areas of the 2014 AF Guideline that were updated were limited to those for which important new data from clinical trials had emerged and/or new U.S. Food and Drug Administration (FDA) indications for thromboembolism protection devices have appeared in the data available to the writing group up to August 2018. All recommendations (new, modified, and unchanged) for each updated clinical section are included to provide a comprehensive assessment. Recommendations from the prior guideline that remain current have been included for completeness.
Key distinctions: 2014 Atrial Fibrillation Guideline - 2019 Focused Update
- ACC/AHA Clinical Practice Guidelines, Focused Update, Acute Coronary Syndrome, Anticoagulants, Anticoagulation Agents, Antiplatelet Agents, Apixaban, Atrial Fibrillation, Atrial
The American College of Cardiology (ACC)—along with collaborative societies—create Clinical Practice Guidelines, which become ACC policy at the time of publication. All Clinical Practice Guidelines undergo rigorous peer review that is independent of the Editors/editorial processes of the Journal of the American College of Cardiology (JACC). JACC Editors receive no compensation from the publication of the guidelines nor other ACC clinical/policy documents. For more information on guideline processes, click here: About Guidelines and Clinical Documents